The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans.
The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans.
复制标题
糖生物学的临床影响：靶向选择素、Siglecs和哺乳动物聚糖。
DOI：
10.1038/s41573-020-00093-1
复制
发表时间：
2021-03
期刊：
影响因子：
--
通讯作者：
Bertozzi CR
中科院分区：
文献类型：
--
作者：
Smith BAH;Bertozzi CR
碳水化合物-即聚糖-装饰在人体内的每一个细胞和大多数分泌的蛋白质。基因组学、糖蛋白质组学和化学生物学工具的进步使糖生物学变得更加易于处理和理解。糖基化失调在从免疫逃避到认知的疾病过程中起着重要作用，引发了旨在靶向聚糖以获得治疗益处的研究。这个领域现在正准备迎来药物开发的繁荣。作为这一活动的先驱，糖生物学已经生产出几种改善人类健康或目前正在转化为临床的药物。聚焦于三个领域-选择素，Siglecs和聚糖靶向抗体-这篇综述旨在讲述受聚糖启发的疗法背后的故事，并概述从这些方法中吸取的经验教训如何为未来以糖生物学为重点的疗法铺平道路。许多蛋白质和脂质被聚糖覆盖，这影响了这些分子相互作用的方式。在这篇综述中，Smith和Bertozzi讨论了靶向识别糖基化的蛋白质的疗法，即选择素和Siglecs，以及已经进入临床或正在开发的聚糖靶向抗体。他们对糖生物学的未来提出了自己的观点。
Carbohydrates — namely glycans — decorate every cell in the human body and most secreted proteins. Advances in genomics, glycoproteomics and tools from chemical biology have made glycobiology more tractable and understandable. Dysregulated glycosylation plays a major role in disease processes from immune evasion to cognition, sparking research that aims to target glycans for therapeutic benefit. The field is now poised for a boom in drug development. As a harbinger of this activity, glycobiology has already produced several drugs that have improved human health or are currently being translated to the clinic. Focusing on three areas — selectins, Siglecs and glycan-targeted antibodies — this Review aims to tell the stories behind therapies inspired by glycans and to outline how the lessons learned from these approaches are paving the way for future glycobiology-focused therapeutics. Numerous proteins and lipids are covered in glycans, which affects the way these molecules interact. In this Review, Smith and Bertozzi discuss therapies targeting proteins that recognize glycosylation, namely the selectins and Siglecs, as well as glycan-targeted antibodies that have entered the clinic or are in development. They provide their perspectives on the future of glycobiology.
登录
查看更多内容
影响因子：
64.5
作者：
ARUFFO, A;KOLANUS, W;SEED, B
通讯作者：
SEED, B
影响因子：
45.3
作者：
Berek, Jonathan;Taylor, Peyton;Nicodemus, Christopher F.
通讯作者：
Nicodemus, Christopher F.
影响因子：
15.9
作者：
BUERKE, M;WEYRICH, AS;LEFER, AM
通讯作者：
LEFER, AM
粘蛋白MUC1通过参与凝集素SIGLEC-9调节肿瘤免疫学微环境。
影响因子：
30.5
作者：
Beatson R;Tajadura-Ortega V;Achkova D;Picco G;Tsourouktsoglou TD;Klausing S;Hillier M;Maher J;Noll T;Crocker PR;Taylor-Papadimitriou J;Burchell JM
通讯作者：
Burchell JM
DOI：
10.1084/jem.174.6.1461
发表时间：
1991-12-01
期刊：
The Journal of experimental medicine
影响因子：
--
作者：
Berg EL;Yoshino T;Rott LS;Robinson MK;Warnock RA;Kishimoto TK;Picker LJ;Butcher EC
通讯作者：
Butcher EC